PPMD's Blog – May 2017 Archive (4)
In Honor of Moms: A Note from Tom Furlong
This Mother’s Day, thank someone for their role in the fight to end Duchenne.
If you’re reading this blog, chances are you know my wife, Pat Furlong. For 23 years now, Pat has been leading Parent Project Muscular Dystrophy (PPMD) and the fight to end Duchenne. Many of you have told me over the years that Pat has been a source of comfort,…
ContinueAdded by PPMD on May 10, 2017 at 10:30am — No Comments
PPMD's 2017 Connect Conference Agenda is Now Available!
PPMD is excited to unveil the agenda for our 2017 Connect Conference in Chicago, June 29 - July 2, 2017!
We are so proud of the …
ContinueAdded by PPMD on May 9, 2017 at 11:00am — No Comments
PPMD's Response to PTC Announcement of EMFLAZA (deflazacort) Pricing & Access
Today, PTC Therapeutics provided a community update on EMFLAZA (deflazacort) which they acquired earlier in the year from Marathon Pharmaceuticals. The community has anxiously awaited an update on both access and pricing ever since the deal between PTC and Marathon was announced.
On today’s call, we…
ContinueAdded by PPMD on May 8, 2017 at 5:38pm — No Comments
PTC Therapeutics to Discuss Launch Plans for Emflaza™ (Deflazacort) during Community Call on Monday, May 8th at 3:00 PM EDT
PTC Therapeutics has released a letter to the community and will host a conference call for the Duchenne community to discuss the launch plans for EMFLAZA™ (deflazacort) on Monday, May 8, 2017 at 3:00 PM EDT (call-in details are below).
On a…
ContinueLatest Blog Posts
- Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
- Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne
- Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
- Roche Restarts RG62026 Phase 2/3 Study
- [WEBINAR] What is a Master Protocol?
- Santhera Shares Duchenne Community Update on SIDEROS Trial
- Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program
Most Popular Blog Posts
- April 25: FDA Advisory Committee Meeting for Eteplirsen - Live Webcast Information
- September 28: FDA Advisory Committee Meeting for Ataluren - Live Webcast Information
- Action ALERT: Urge Congress to Vote YES on 21st Century Cures Act
- Summit Receives Fast Track Designation from FDA for Ezutromid in the Treatment of Duchenne
- Ongoing Traumatic Stress
- PTC Therapeutics to Discuss Launch Plans for Emflaza™ (Deflazacort) during Community Call on Monday, May 8th at 3:00 PM EDT
- Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 & SRP-4053
Monthly Archives
2018
2017
- December (11)
- November (8)
- October (7)
- September (10)
- August (2)
- July (1)
- June (7)
- May (5)
- April (8)
- March (9)
- February (6)
- January (7)
2016
- December (5)
- November (4)
- October (11)
- September (7)
- August (5)
- July (7)
- June (5)
- May (3)
- April (10)
- March (7)
- February (5)
- January (9)
2015
- December (16)
- November (5)
- October (7)
- September (4)
- August (5)
- July (10)
- June (6)
- May (4)
- April (2)
- March (4)
- February (5)
- January (3)
2014
- December (5)
- November (3)
- October (5)
- September (3)
- August (2)
- July (9)
- June (6)
- May (7)
- April (40)
- March (17)
- February (2)
- January (3)
2013
- December (19)
- November (52)
- October (1)
- September (4)
- August (3)
- July (1)
- June (4)
- May (4)
- April (7)
- March (8)
- February (5)
- January (3)
2012
- December (3)
- November (2)
- October (4)
- September (2)
- August (1)
- July (1)
- June (1)
- May (2)
- April (1)
- March (4)
- February (8)
- January (1)
2011
2010
© 2019 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
